secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001140361-22-041172
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin reports Q3 2022 net loss $8.6M; NAVIGATE trial 88% enrolled
--------------------------------------------------------------------

- Net loss $8.6M ($0.14/sh) for Q3 2022, unchanged from Q3 2021.
- Cash $15.8M; plus $60M credit line; expects funding through Dec 2024.
- NAVIGATE trial: 279 of 315 patients randomized, 74 in screening; target full enrollment around end-2022.
- FDA allowed IND for belapectin + Keytruda in head and neck cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036122041172/0001140361-22-041172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036122041172/brhc10044046-8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-041172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer